EFFICACY OF 17-α-HYDROXY-PROGESTRONE IN PREVENTION OF PRETERM LABOR IN HIGH RISK PREGNANT WOMEN
AbstractBackground: Preterm delivery (before 37 completed weeks of gestation) is a major determinant of infant mortality. The objective of study was to determine the efficacy of 17-alpha hydroxy-progesterone in preventing delivery before 37 weeks of gestation in high risk women. Methods: This study, a randomized controlled trial was conducted in Obstetrics OPD, observing all scientific and ethical protocols. The women with less than 20 weeks gestation and with a past history of preterm delivery were included. A total of 132 women fulfilled the study requirements. Two groups made were as follows: Group A (Treatment group received intramuscular 17-alpha hydroxy-progesterone) and Group B served as control (The control group revived intramuscular Neurobion). A total of 66 women were assigned to each group. The data was recorded on a specially designed proforma for statistical analysis and comparison following the standard procedure. Results: The criterion was strictly observed. The results showed a statistically significant (p<0.01) difference between group A as compared to group B. Conclusion: 17-α-Hydroxyprogesterone was found to be an effective drug in preventing delivery before 37 weeks in women at risk.Keywords: 17-Alpha-hydroxyprogesterone; Preterm labour; High risk pregnancy
Butler AS, Behrman RE, editors. Preterm birth: causes, consequences, and prevention. Washington (DC): National Academies Press; 2007.
Rush RW, Davey DA, Segall ML. The effect of preterm delivery on perinatal mortality. Br J Obstet Gynaecol 1978;85(11):806–11.
Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study. Am J Obstet Gynecol 2017;216(6):e600–1.
O’Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30(5):687–96.
Bittar ER, Yamasaki AA, Sasaki S, Zugaib M. Cervical fetal fibronectina in patients at increased risk for preterm delivery. Am J Obstet Gynecol 1996;175(1):178–81.
Cunningham FG, Gant NF, Leveno KJ, Gilstrap III LC, Hauth JC, Wenstrom KD. Preterm and postterm pregnancy and fetal growth retardation. In: Williams’ obstetrics. 20th ed. New Jersey: Prentice-Hall International, 1997; p.797–826.
Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol 1986;154(3):525–9.
Check JH, Lee G, Epstein R, Vetter B. Increased rate of preterm deliveries in untreated women with luteal phase deficiencies. Gynecol Obstet Invest 1992;33(3):183–4.
Lockwood CJ, Senyei AE, Dischie MR, Casal D, Shah KD, Thug SN, et al. Fetal fibronectina in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991;325(10):669–74.
Michal A, Elovitz, MD, Conjecvarm M. The use of progestational agents for preterm birth: lessons from a mouse model. Am J Obstet Gynecol 2006;195(4):1004–10.
Society for Maternal-Fetal Medicine (SMFM) Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol 2017;216(3):B11–3.
Romero R, Yeo L, Miranda J, Hassan SS, Conde-Agudelo A, Chaiworapongsa T. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med 2013;41(1):27–44.
Paneth NS. The problem of low birth weight. Future Child 1995;5(1):19–34.
Mattison DR, Damus K, Fiore E, Petrini J, Alter C. Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol 2001;15(2):7–16.
Creasy RK. Preterm birth prevention: where are we? Am J Obstet Gynecol 1993;168(4):1223–30.
Johnson JW, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293(14):675–80.
Hauth JC, Gilstrap LC 3rd, Brekken AL, Hauth JM. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983;146(2):187–90.
Hobel CJ, Ross MG, Bemis RL, Bragonier JR, Nessim S, Sandhu M, et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. Am J Obstet Gynecol 1994;170(1 Pt 1):54–62.
Fuchs F, Stakemann G. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol 1960;79:172–6.
Fuchs AR, Fuchs F. Endocrinology of human parturition: a review. Br J Obstet Gynaecol 1984;91(10):948–67.
American college of obstetricians and gynaecologists. ACOG committee opinion: use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102(5 Pt 1):1115–6.
Rittenberg C, Newman RB, Istwan NB, Rhea DJ, Stanziano GJ. Preterm birth prevention by 17 alpha-hydroxyprogesteronecaproate vs. Daily Nursing Surveillance. J Reprod Med 2009;54(2):47–52.